How Merck’s Keytruda became a global immunotherapy benchmark in cancer treatment

Keytruda, also known by its generic name pembrolizumab, has become one of the most widely prescribed and researched immunotherapy drugs in modern oncology. Developed by Merck & Co., this PD-1 checkpoint inhibitor has reshaped how cancer is treated, moving beyond traditional cytotoxic regimens toward immune-guided therapies that offer durable responses and precision-based decision-making. Since its first regulatory approval over a decade ago, Keytruda has expanded into more than 18 distinct cancer types and dozens of treatment settings—ranging from metastatic disease to adjuvant and neoadjuvant protocols. In 2025, it continues to redefine clinical expectations and global market dynamics.

The success of Keytruda is not accidental. It is the result of deliberate molecular development, strategic trial design, and an expansive biomarker-led regulatory strategy that now influences every tier of oncology innovation. Understanding how Keytruda evolved from a scientific hypothesis into a multibillion-dollar global therapy reveals the deeper shifts in drug development, cancer biology, and healthcare access that will continue shaping the sector through 2030.

What is Keytruda and how does it target the PD-1 pathway in cancer?

Pembrolizumab is a monoclonal antibody that targets the PD-1 receptor found on activated T-cells. In many cancers, the PD-1 receptor is bound by its ligand, PD-L1, which is often overexpressed on tumor cells. This binding essentially turns off the immune response, allowing the tumor to evade detection. By blocking this interaction, Keytruda helps re-engage the immune system’s ability to recognize and destroy cancer cells. The science behind this mechanism is now foundational to modern immuno-oncology, but when Keytruda entered clinical trials in the early 2010s, the concept of checkpoint inhibition was still emerging from preclinical research.

The PD-1/PD-L1 axis is especially relevant in cancers with a high mutational burden, where tumor cells present more antigens and are therefore more visible to immune surveillance once immune suppression is lifted. Keytruda was designed to interrupt this immune escape pathway, and early clinical trials confirmed its efficacy in tumors that had previously shown poor response to chemotherapy, such as advanced melanoma and non-small cell lung cancer.

How was Keytruda discovered and what led to its first FDA approval?

The molecule that would become Keytruda originated in research labs at Organon, a Dutch pharmaceutical company. After a series of corporate mergers and acquisitions, including Organon’s absorption into Schering-Plough and later Merck & Co., the molecule—then known as MK-3475—was selected for its potential to inhibit PD-1 in vivo. Merck moved the drug into clinical trials around 2011, with a global clinical program branded under the KEYNOTE banner. KEYNOTE-001, a Phase I trial in advanced melanoma patients, produced response rates that were remarkable for the time and laid the foundation for accelerated FDA review.

In September 2014, Keytruda received its first approval from the U.S. Food and Drug Administration for the treatment of advanced melanoma following ipilimumab failure. This milestone not only marked the arrival of a new class of cancer therapeutics but also triggered an intense wave of investment and trial expansion across multiple tumor types.

How did Keytruda’s clinical development expand through the KEYNOTE program?

What distinguishes Keytruda from many other oncology drugs is the scale and depth of its clinical evidence base. Merck’s KEYNOTE trial program became a model for simultaneous, multi-indication global development, with studies often running in parallel across cancer types. Within a few years of its initial approval, Keytruda received additional FDA clearances for non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, and microsatellite instability-high cancers, among others.

Each new approval was based on prospective, statistically powered trials that assessed both progression-free and overall survival, often using PD-L1 expression as a companion diagnostic marker. Keytruda was also the first immunotherapy to receive a tissue-agnostic FDA approval, based on genetic profile rather than tumor origin, in MSI-H or mismatch repair-deficient cancers—a major regulatory precedent that would later be followed by other precision medicines.

By 2025, Keytruda has amassed regulatory approvals across more than 39 labeled uses globally and is entrenched in standard-of-care guidelines across first-line, adjuvant, and perioperative settings. Its most recent additions include FDA-approved use in HER2-positive, PD-L1-expressing gastric cancer, and as perioperative therapy in resectable head and neck squamous cell carcinoma.

How is Keytruda used across different cancer types in clinical practice?

The clinical versatility of Keytruda is reflected in its use across multiple cancer pathways. In non-small cell lung cancer, it is approved both as monotherapy in PD-L1 high expressers and in combination with chemotherapy for broader patient populations. In melanoma, it remains a go-to treatment across early and advanced stages, particularly for patients without BRAF mutations. In triple-negative breast cancer, its combination with chemotherapy has shown improvement in both progression-free and overall survival for patients with PD-L1 expression.

Keytruda is also used in microsatellite instability-high colorectal and endometrial cancers, where immune checkpoint inhibition has proven particularly effective. In bladder cancer, it has an adjuvant indication following surgical resection. In gastric and gastroesophageal junction cancers, new combination regimens have brought pembrolizumab into frontline settings with trastuzumab and platinum-based chemotherapy.

These varied uses underscore the drug’s adaptability and the evolving clinical understanding of immune sensitivity across tumor types.

How does the global market for Keytruda compare across the U.S., Europe, India, and other regions?

The global market for Keytruda is both expansive and highly stratified. In the United States, it benefits from broad payer coverage and ongoing label expansion, contributing to nearly half of its global revenue. Europe follows closely, with the drug receiving approvals from the European Medicines Agency for most of the same indications, although pricing and health technology assessment constraints sometimes delay uptake.

In India, Keytruda is available but remains largely restricted to private-sector use due to its high cost. As of 2025, the Indian market remains a strategic but under-penetrated opportunity, with total sales estimated to reach approximately USD 1.2 billion by the end of the decade, despite low current adoption. Efforts to improve affordability through local partnerships, expanded access programs, and outcome-based reimbursement models are under discussion but not yet widespread.

Australia and Canada have included Keytruda in their respective public formularies for multiple indications, although coverage can vary by province or cancer type. Across Latin America, access is more limited and often tied to philanthropic programs or international procurement agreements.

What safety concerns or limitations are associated with Keytruda therapy?

Checkpoint inhibitors like Keytruda are not without side effects. The most common adverse events stem from immune activation in non-target tissues, leading to conditions such as pneumonitis, hepatitis, colitis, and endocrine dysfunction. These immune-related adverse events require prompt recognition and intervention, often involving corticosteroids or discontinuation of therapy.

Another limitation is that not all patients respond to Keytruda. Biomarker-negative tumors, immunologically “cold” cancers, and those with low tumor mutational burden often exhibit minimal benefit. Researchers are actively exploring combination strategies to convert these non-responders into responders by altering the tumor microenvironment.

Cost and duration of therapy also remain key concerns. Some patients may receive immunotherapy for years, raising questions about long-term safety, resistance mechanisms, and the economic burden on healthcare systems.

What new innovations are reshaping Keytruda’s formulation and therapeutic positioning?

Merck is investing in a subcutaneous version of Keytruda designed for faster and more convenient administration. Early data in 2025 suggest this format may achieve similar pharmacokinetics to intravenous infusion but with far shorter delivery times—less than five minutes compared to the typical 30–60 minutes via IV. This could be a game-changer for outpatient clinics, particularly in regions with limited infusion infrastructure.

In parallel, Keytruda is being tested in combinations with novel drug classes. These include mRNA cancer vaccines such as Moderna’s mRNA-4157, which has shown substantial reduction in recurrence among melanoma patients, and antibody-drug conjugates like sacituzumab govitecan (Trodelvy) in triple-negative breast cancer. Trials are also exploring combinations with TLR agonists, STING activators, and bispecific antibodies to enhance response rates in tumors that are less immune-sensitive.

These developments point to a broader evolution of Keytruda—from a single-agent checkpoint inhibitor to a foundational element within complex immuno-oncology regimens.

What does the future hold for Keytruda as biosimilar competition and AI-driven oncology reshape the landscape?

As Keytruda approaches patent expiry in major markets like the U.S. and Europe (expected post-2028), biosimilar developers are already positioning to enter. However, the complexity of biologic manufacturing and the high regulatory standards for immunotherapies may delay rapid adoption of biosimilars, giving Merck time to transition Keytruda into a broader platform anchored in real-world evidence, AI-assisted patient stratification, and digital companion diagnostics.

Merck is also integrating Keytruda into long-term precision oncology strategies. These include adaptive dosing schedules, machine learning models to predict response and toxicity, and integration into decision support tools used by oncologists worldwide. This shift aligns with the growing movement toward value-based cancer care, where clinical efficacy must be balanced with real-world utility and cost efficiency.